期刊文献+

上皮细胞黏附分子表达与乳腺癌的分子分型及预后 被引量:4

Expression of epithelial cell adhesion molecule and molecular subtypes and prognosis of breast cancer
下载PDF
导出
摘要 目的:探讨上皮细胞黏附分子(epithelial cell adhesion molecule,Ep CAM)在乳腺癌及其分子亚型中表达的临床病理及预后意义。方法:采用免疫组织化学Max VisionTM法检测835例乳腺浸润性导管癌中Ep CAM的表达,分析其与临床病理特征和预后的关系。结果:Ep CAM的阳性表达与组织学分级、淋巴结转移、肿瘤大小、ER和PR表达、HER2表达和临床分期均有关(均P<0.05),与绝经状态无关(χ2=0.117,P=0.733)。在腺腔A型、腺腔B型(HER2-)、腺腔B型(HER2+)、HER2过表达型及三阴型乳腺浸润性导管癌(invasive ductal carcinoma,IDC)中,Ep CAM的阳性表达率分别为19.2%,73.0%,48.9%,72.2%和62.1%。Log-rank检验和单因素COX分析显示Ep CAM阳性患者的预后较差(均P<0.001),并与三阴型、腺腔B型(HER2-)和HER2过表达型预后有关(均P<0.05)。多因素COX分析显示Ep CAM阳性表达与三阴型和HER2过表达型预后差相关(均P<0.05)。结论:Ep CAM可能与乳腺癌进展有关,并与分子分型相关,在乳腺癌总体上及三阴型和HER2过表达型中是一种独立的预后因子。 Objective: To investigate clinicopathological and prognostic significance of epithelial cell adhesion molecule(Ep CAM) expression in breast cancer and its molecular subtypes.Methods: The expression of Ep CAM in 835 patients with breast invasive ductal carcinoma was detected by immunohistochemical Max VisionTM method, and its correlation with clinical pathological features and prognosis was analyzed.Results: The positive expression of Ep CAM was related to histological grade, lymph node metastasis, tumor size, clinical stage, the expression of estrogen receptor(ER), progesterone receptor(PR) and HER2(P〈0.05). The positive expression rates of Ep CAM were 19.2%, 73%,48.9%, 72.2%, and 62.1%, in Luminal A, Luminal B(HER2-), Luminal B(HER2+), HER2+, and triple-negative subtype, respectively. Log-rank test and univariate COX analysis showed that the Ep CAM expression was associated with a poor prognosis in all patients(P0.001), as well as the triple-negative subtype, luminal B subtype(HER2-), and HER2+ subtype(P〈0.05). Multivariate COX analysis showed that Ep CAM expression was associated with the survival in patients with the triple-negative or HER2+ subtype(P〈0.05).Conclusion: Ep CAM may be associated with progress of breast cancer. It is an independent prognostic factor in breast cancer, especially in the triple-negative and HER2+ subtypes.
出处 《中南大学学报(医学版)》 CAS CSCD 北大核心 2016年第3期258-263,共6页 Journal of Central South University :Medical Science
基金 山东省科技发展计划(政策引导类)(2013YD18032)~~
关键词 乳腺肿瘤 分子亚型 上皮细胞黏附分子 breast neoplasms molecular subtypes epithelial cell adhesion molecule
  • 相关文献

参考文献13

  • 1Patriarca C, Macchi RM, Marschner AK, et al. Epithelial celladhesion molecule expression(CD326) in cancer: a short review[j].Cancer Treat Rev, 2012, 38(1): 68-75.
  • 2Baeuerle PA, Gires O. EpCAM(CD326) finding its role in cancer[j].BrJ Cancer, 2007,96(3): 417-423.
  • 3Goldhirsch A, Winer EP, Coates AS, et al. Personalizing thetreatment of women with early breast cancer: highlights of the StGallen International Expert Consensus on the Primary Therapy ofEarly Breast Cancer 2013[j]. Ann Oncol, 2013,24(9): 2206-2223.
  • 4Soysal SD, Muenst S, Barbie T, et al. EpCAM expression variessignificantly and is differentially associated with prognosis in theluminal B HER2(+), basal-like, and HER2 intrinsic subtypes ofbreast cancer[j]. BrJ Cancer, 2013,108(7): 1480-1487.
  • 5乳腺癌HER2检测指南(2014版)[J].中华病理学杂志,2014,43(4):262-267. 被引量:295
  • 6Dittmer J, Rody A. Cancer stem cells in breast cancer[j]. HistolHistopathol, 2013,28(7): 827-838.
  • 7Lee M. Prognostic impact of epithelial cell adhesion molecule inovarian cancer patients[J].J Gynecol Oncol, 2014,25(4): 352-354.
  • 8Agboola AJ, Paish EC, Rakha EA, et al. EpCAM expression is anindicator of recurrence in basal-like breast cancer[j]. Breast CancerRes Treat, 2012,133(2): 575-582.
  • 9李金梅,张金库,周炳娟,赵文明,陈红,孙吉瑞,张丙信,乔海芝.三阴性乳腺癌中EpCAM和Sox2的表达及临床意义[J].临床与实验病理学杂志,2014,30(9):1040-1042. 被引量:4
  • 10Sebastian M, Kiewe P, Schuette W, et al. Treatment ofmalignant pleural effusion with the trifunctional antibodycatumaxomab(Removab) (anti-EpCAM x Anti-CD3): results of aphase 1/2 study[j].j Immunother, 2009, 32(2): 195-202.

二级参考文献36

  • 1张瑰红,施达仁,梁晓曼,侯景辉,康苏娅,朱卫东,李晓兵,邵云,陈丽荣,周燕.显色原位杂交和免疫组织化学检测乳腺癌HER2/neu基因状况和蛋白表达的对照性研究[J].中华病理学杂志,2006,35(10):580-583. 被引量:29
  • 2<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:164
  • 3Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer [ J]. J Clin Oncol, 2007, 25 (33) :5287-5312.
  • 4Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Chnical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer[ Jl. J Clin Oncol, 2007, 25 ( 1 ) : 118- 145.
  • 5Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth faetor reeeptor 2 testing in breast eaneer: American Society of Clinical Oneology/College of American Pathologists clinical practice guideline update[J]. J Clin Oneol, 2013, 31 (31) :3997-4013.
  • 6Hanna WM, Kwok K. Chromogenic in-situ hybridization:a viable ahernative to fluorescence in-situ hybridization in the HER2 testing algorithm[J]. Mod Pathol, 2006, 19(4) :481-487.
  • 7Park K, Han S, Kim JY, et al. Silver-enhanced in situ hybridization as an alternative to fluorescence in situ hybridization for assaying HER2 amplification in clinical breast cancer [ J ]. J Breast Cancer, 2011, 14(4) :276-282.
  • 8Haines GK 3rd, Wiley E, Susnik B, et al. HER2 in well differentiated breast cancer: is testing necessary? [ J ]. Breast Cancer Res Treat, 2008, 112(3) :551-556.
  • 9Zhu X, Lu Y, Lu H, et al. Genetic alterations and protein expression of HER2 and chromosome 17 polysomy in breast cancer [J]. Hum Pathol, 2011,42(10) : 1499-1504.
  • 10Marchio C, Lambros MB, Gugliotta P, et al. Does chromosome 17 centromere copy number predict polysomy in breast cancer.9 A fluorescence in situ hybridization and microarray-based CGH analysis[ J]. J Pathol, 2009, 219( 1 ) : 16-24.

共引文献295

同被引文献54

引证文献4

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部